Stanford Cancer Institute

Stanford MEDICINE

Stanford Cancer Institute Genitourinary

Version Date:
January 20, 2023

Prostate

Recurrent Non-Metastatic HSPC Post Definitive Local Therapy

PROS0111
Phase II MBM-02 (Tempol) in Prostate Cancer in Biochemical Recurrence

PI: Srinivas
Sponsor: Matrix Biomed, Inc.

ECOG-ACRIN-EA8183
Eradicate. Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy w/ Darolutamide vs. Placebo in Highest Risk of Prostate Cancer Metastasis by Genomic Stratification

PI: Khaki
Sponsor: NCTN, ECOG-ACRIN

Metastatic Castration Sensitive

ECOG-ACRIN-S1802
Phase III Standard Systemic Therapy (SST) vs Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
.
PI: Sonn
Sponsor: SWOG

Rising PSA before and after study:
PROS0100
Phase I Tolerability/ Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

PI: Stafford
Sponsor: Stanford University

Localized Treatment

Intact Prostate

PROS0107
Focal Laser Ablation of Prostate Cancer: EarlyFeasibility Study Using MRI/US ImageFusion for Guidance

PI:Sonn
Sponsor: Pending

NRGGU009
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk & Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

PI: Bagshaw
Sponsor: NRG

PROS0093
Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

PI: Iagaru
Sponsor: Stanford University

PROS0122
Open-Label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer

PI: Sonn
Sponsor: SpectraCure AB

PROS0124
Customized Ablation of the Prostate with the TULSA Procedure Against RadIcal Prostatectomy TreatmeNt: a Randomized Controlled Trial for Localized Prostate Cancer

PI: Sonn
Sponsor: Profound Medical, Inc.

Metastatic Hormone Sensitive

PROS0113
Phase III 177Lu-PSMA-617 +/- Standard of Care in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

PI: Iagaru
Sponsor: Novartis Pharmaceuticals, Corporation

PROS0108
Prostatic Artery Embolization in Treatment of LUTS in Prostate Cancer Undergoing Radiation Therapy

PI:Picel
Sponsor: Stanford University

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu